Abiopharma

🔍 Patel Naimish (Executive)

Company: CRISPR Therapeutics AG (CRSP)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 38,499 shares of Stock Option (Right to Buy) at $46.24 per share (Derivative)
  Date: 2026-03-20 | Code: A | Expires: 2036-03-20 | equity_swap_involved: false | shares_owned_after: 38,499.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 30,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-20 | Code: A | equity_swap_involved: false | shares_owned_after: 30,000.00 | transaction_form_type: 4 | Footnotes: F3, F1, F4, F4

Footnotes:

• F1: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
• F2: This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.
• F3: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
• F4: This restricted stock unit award was granted on March 20, 2026 with respect to 30,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.